212 related articles for article (PubMed ID: 17101065)
61. New strategies for treating GIST when imatinib fails.
Boyar MS; Taub RN
Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
[TBL] [Abstract][Full Text] [Related]
62. Advances in adjuvant therapy of gastrointestinal stromal tumors.
Adekola K; Agulnik M
Curr Oncol Rep; 2012 Aug; 14(4):327-32. PubMed ID: 22535506
[TBL] [Abstract][Full Text] [Related]
63. A large esophageal gastrointestinal stromal tumor that was successfully resected after neoadjuvant imatinib treatment: case report.
Yanagawa S; Tanabe K; Suzuki T; Tokumoto N; Arihiro K; Ohdan H
World J Surg Oncol; 2014 Feb; 12():47. PubMed ID: 24575748
[TBL] [Abstract][Full Text] [Related]
64. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
65. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Pantaleo MA; Di Battista M; Catena F; Astorino M; Saponara M; Di Scioscio V; Santini D; Piazzi G; Castellucci P; Brandi G; Biasco G
J Cancer Res Clin Oncol; 2008 May; 134(5):625-30. PubMed ID: 18202855
[TBL] [Abstract][Full Text] [Related]
66. Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report.
Ciresa M; D'Angelillo RM; Ramella S; Cellini F; Gaudino D; Stimato G; Fiore M; Greco C; Nudo R; Trodella L
Tumori; 2009; 95(2):236-9. PubMed ID: 19579872
[TBL] [Abstract][Full Text] [Related]
67. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy.
Joensuu H; DeMatteo RP
Annu Rev Med; 2012; 63():247-58. PubMed ID: 22017446
[TBL] [Abstract][Full Text] [Related]
68. Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum.
Fujimoto Y; Akiyoshi T; Konishi T; Nagayama S; Fukunaga Y; Ueno M
Int J Colorectal Dis; 2014 Jan; 29(1):111-6. PubMed ID: 24018650
[TBL] [Abstract][Full Text] [Related]
69. Controversies in the surgical management of GIST in the era of imatinib.
Raut CP; Bertagnolli MM
Oncology (Williston Park); 2009 Jan; 23(1):69, 74-6. PubMed ID: 19283924
[TBL] [Abstract][Full Text] [Related]
70. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Hohenberger P; Eisenberg B
Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
[TBL] [Abstract][Full Text] [Related]
71. [GIST: adjuvant treatment in Austria].
Brodowicz T; Kühr T
Wien Med Wochenschr; 2009; 159(15-16):399-402. PubMed ID: 19696984
[TBL] [Abstract][Full Text] [Related]
72. Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case.
Ludvigsen L; Toxvaerd A; Mahdi B; Krarup-Hansen A; Bergenfeldt M
Surg Today; 2007; 37(12):1105-9. PubMed ID: 18030576
[TBL] [Abstract][Full Text] [Related]
73. [Surgical treatment of an advanced GIST the age of imatinib].
Fernández JA; Parrilla P
Cir Esp; 2009 Jul; 86(1):3-12. PubMed ID: 19539273
[TBL] [Abstract][Full Text] [Related]
74. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
75. The role of imatinib plasma level testing in gastrointestinal stromal tumor.
George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S45-50. PubMed ID: 21140148
[TBL] [Abstract][Full Text] [Related]
76. [Surgical treatment of gastrointestinal stromal tumors].
Bareck E; Längle F; Zacherl J
Wien Med Wochenschr; 2009; 159(15-16):393-8. PubMed ID: 19696983
[TBL] [Abstract][Full Text] [Related]
77. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
Cohen MH; Cortazar P; Justice R; Pazdur R
Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
[TBL] [Abstract][Full Text] [Related]
78. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
79. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.
Wilkinson MJ; Fitzgerald JE; Strauss DC; Hayes AJ; Thomas JM; Messiou C; Fisher C; Benson C; Tekkis PP; Judson I
Br J Surg; 2015 Jul; 102(8):965-71. PubMed ID: 25970743
[TBL] [Abstract][Full Text] [Related]
80. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
Rink L; Skorobogatko Y; Kossenkov AV; Belinsky MG; Pajak T; Heinrich MC; Blanke CD; von Mehren M; Ochs MF; Eisenberg B; Godwin AK
Mol Cancer Ther; 2009 Aug; 8(8):2172-82. PubMed ID: 19671739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
